To evaluate Australian psychiatrists’ and psychiatry trainees’ information about and attitudes in the direction of medicinal cannabinoids, given the latest rest of cannabinoid-prescribing legal guidelines in Australia.
All Australian members of the Royal Australian and New Zealand Faculty of Psychiatrists have been invited to take part in an nameless, 64-item on-line questionnaire, by Royal Australian and New Zealand Faculty of Psychiatrists’ newsletters. The questionnaire ran for a 10-week interval from March to Could 2017. Members have been requested about their information of the proof for and in opposition to prescribing pharmaceutical-grade cannabidiol and tetrahydrocannabinol, and their considerations about prescribing medicinal cannabinoids.
In whole, 88 medical doctors responded to the survey, with 55 finishing all gadgets (23 psychiatrists, 32 trainees). General, 54% of respondents would prescribe medicinal cannabinoids if it was authorized to take action. Members believed there was proof for using cannabidiol and tetrahydrocannabinol in treating childhood epilepsy, continual ache, and nausea and vomiting. They have been most involved about medicinal cannabinoids resulting in psychotic signs, habit and dependence, apathy and leisure use.
Our pattern of Australian psychiatrists and trainees have been conscious of the principle medical indications for medicinal cannabinoids, however have been poor at differentiating between the indications for cannabidiol versus tetrahydrocannabinol. Additional schooling about medicinal cannabinoids seems essential.